Clinical manifestations and treatment outcome of optic neuropathy in thyroid-related orbitopathy

Ophthalmic Surgery Lasers and Imaging

Volumn 37, Issue 4, 2006, Pages 284-290

  Ben Simon, Guy J ^a,b   Syed, Hasan ^a   Douglas, Raymond ^a   Schwartz, Robert ^a   Goldberg, Robert A ^a   McCann, John D ^a  

^a JULES STEIN EYE INSTITUTE   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PREDNISONE; STEROID; TRIAMCINOLONE;

ADULT; AGED; CLINICAL FEATURE; CONTROLLED STUDY; DECOMPRESSION SURGERY; DEMOGRAPHY; DISEASE ASSOCIATION; ELECTRONIC MEDICAL RECORD; EXOPHTHALMOS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OPTIC NERVE; OPTIC NERVE DISEASE; ORBIT DISEASE; ORBITOPATHY; PRIORITY JOURNAL; PUPIL DISEASE; REVIEW; THYROID DISEASE; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 33746688603     PISSN: 15428877     EISSN: None     Source Type: Journal    
DOI: 10.3928/15428877-20060701-04     Document Type: Review

References (28)

1. Neigel JM, Rootman J, Belkin RI, et al. Dysthyroid optic neuropathy: the crowded orbital apex syndrome. Ophthalmology. 1988;95:1515-1521.
2. Kennerdell JS, Rosenbaum AE, El-Hoshy MH. Apical optic nerve compression of dysthyroid optic neuropathy on computed tomography. Arch Ophthalmol. 1981;99:807-809.
3. Gass A, Barker GJ, MacManus D, et al. High resolution magnetic resonance imaging of the anterior visual pathway in patients with optic neuropathies using fast spin echo and phased array local coils. J Neurol Neurosurg Psychiatry. 1995;58:562-569.
4. Giaconi JA, Kazim M, Rho T, Pfaff C. CT scan evidence of dysthyroid optic neuropathy. Ophthal Plast Reconstr Surg. 2002;18:177-182.
5. Trobe JD, Glaser JS, Laflamme P. Dysthyroid optic neuropathy: clinical profile and rationale for management. Arch Ophthalmol. 1978;96:1199-1209.
6. Kalmann R, Mounts MP. Diabetes mellitus: a risk factor in patients with Graves' orbitopathy. Br J Ophthalmol. 1999;83:463-465.
7. Anderson RL, Tweeten JP, Patrinely JR, Garland PE, Thiese SM. Dysthyroid optic neuropathy without extraocular muscle involvement. Ophthalmic Surg. 1989;20:568-574.
8. Claridge KG, Ghabrial R, Davis G, et al. Combined radiotherapy and medical immunosuppression in the management of thyroid eye disease. Eye. 1997;11:717-722.
9. Guy JR, Fagien S, Donovan JP, Rubin ML. Methylprednisolone pulse therapy in severe dysthyroid optic neuropathy. Ophthalmology. 1989;96:1048-1052.
10. Ph Mourits M, Kalmann R, Sasim IV. Methylprednisolone pulse therapy for patients with dysthyroid optic neuropathy. Orbit. 2001;20:275-280.
11. Kinyoun JL, Kalina RE, Brower SA, Mills RP, Johnson RH. Radiation retinopathy after orbital irradiation for Graves' ophthalmopathy. Arch Ophthalmol. 1984;102:1473-1476.
12. Rush S, Winterkorn JM, Zak R. Objective evaluation of improvement in optic neuropathy following radiation therapy for thyroid eye disease. Int J Radiat Oncol Biol Phys. 2000;47:191-194.
13. Hutchison BM, Kyle PM. Long-term visual outcome following orbital decompression for dysthyroid eye disease. Eye. 1995;9:578-581.
14. Liao SL, Kao SC, Hou PK, Chen MS. Results of orbital decompression in Taiwan. Orbit. 2001;20:267-274.
15. Asaria RH, Koay B, Elston JS, Bates GE. Endoscopic orbital decompression for thyroid eye disease. Eye. 1998;12:990-995.
16. Gormley PD, Bowyer J, Jones NS, Downes RN. The sphenoidal sinus in optic nerve decompression. Eye. 1997;11:723-726.
17. Kazim M, Trokel SL, Acaroglu G, Elliott A. Reversal of dysthyroid optic neuropathy following orbital fat decompression. Br J Ophthalmol 2000;84:600-605.
18. Ambrosio G, Ferrara G, Vitale R, De Marco R. Visual evoked potentials in patients with Graves' ophthalmopathy complicated by ocular hypertension and suspect glaucoma or dysthyroid optic neuropathy. Doc Ophthalmol 2003;106:99-104.
19. De Marco R, Ambrosio G, Ferrara G. Measuring contrast sensitivity in patients with Graves' ophthalmopathy complicated by ocular hypertension and suspect glaucoma or dysthyroid optic neuropathy. Doc Ophthalmol. 2000;101:165-77.
20. Suttorp-Schulten MS, Tijssen R, Mourits MP, Apkarian P. Contrast sensitivity function in Graves' ophthalmopathy and dysthyroid optic neuropathy. Br J Ophthalmol 1993;77:709-712.
21. Tsaloumas MD, Good PA, Burdon MA, Misson GP. Flash and pattern visual evoked potentials in the diagnosis and monitoring of dysthyroid optic neuropathy. Eye. 1994;8:638-645.
22. The Optic Neuritis Study Group. Visual function 5 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol. 1997;115:1545-1552.
23. Frederiksen JL, Sorensen TL, Sellebjerg FT. Residual symptoms and signs after untreated acute optic neuritis: a one-year follow-up. Acta Ophthalmol Scand. 1997;75:544-547.
24. Schneck ME, Haegerstrom-Portnoy G. Color vision defect type and spatial vision in the optic neuritis treatment trial. Invest Ophthalmol Vis Sci. 1997:38:2278-2289.
25. Nichols BE, Thompson HS, Stone EM. Evaluation of a significantly shorter version of the Farnsworth-Munsell 100-hue test in patients with three different optic neuropathies. Neuro-ophthalmology. 1997;17:1-6.
26. Trobe JD, Beck RW, Moke PS, Cleary PA. Contrast sensitivity and other vision tests in the Optic Neuritis Treatment Trial. Am J Ophthalmol. 1996;121:547-553.
27. Kalmann R, Mourits MP. Prevalence and management of elevated intraocular pressure in patients with Graves' orbitopathy. Br J Ophthalmol. 1998;82:754-757.
28. Otto AJ, Koornneef L, Mourits MP, Deen-van Leeuwen L. Retrobulbar pressures measured during surgical decompression of the orbit. Br J Ophthalmol. 1996;80:1042-1045.